Alex Brill Featured in Foundation for Economic Education Article
On fee.org, the website for the Foundation for Economic Education, author Brad Polumbo reported on Alex Brill’s estimates of the true cost of the American Rescue Plan.
Alex Brill Quoted in ‘The National Interest’ Article on Global Tax Hike
Alex Brill was recently quoted in Rachel Bucchino’s article on nationalinterest.org, “Joe Biden Is Leading the Charge on a Big Global Tax Hike.” The article examines Treasury Secretary Janet Yellen’s work on a global minimum tax for multinational corporations.
MGA Analysis of Potential Savings from Complex Generics Cited in Multiple Publications
This week, three publications in the healthcare policy and regulatory affairs industries referenced MGA’s recent report on the potential savings from accelerating US approval of complex generics.
Nursing Homes Prepare for Third COVID-19 Surge
“‘The nursing home COVID crisis in New York and New Jersey and Connecticut from the beginning of the pandemic, things are different and way better there. But as the pandemic is spreading throughout the country, we’re going to see it pop up in other nursing homes’ Brill said.”
Trump Roils Markets with Conflicting Statements on Pandemic Relief
“‘I think it creates confusion for the negotiators. Republicans on the Hill are looking for a signal from the president. They are looking for leadership on this, and he’s oscillating,’ Brill said.”
Ending Prescription Drug ‘Product Hopping’ Could Save $4.7 Billion Annually
“The report finds that extending patents on just those five drugs [Prilosec, TriCor, Suboxone, Doryx, and Namenda] will result in a cost to the U.S. health care system of $4.7 billion annually—money that in theory could have been saved if the drugs had been available in a generic form.”
- Alex Brill Featured in Axios
- The Disparate State Impacts and Enormous Cost of a Gas Tax Holiday
- ‘Facing the Future’: Alex Brill discusses tax code and budget challenges
- 2026 Portman Center Symposium: Building an Achievable Fiscal Policy
- Senator Booker’s Costly Standard Deduction Proposal Would Reduce Charitable Giving
- FDA Continues to Expedite Biosimilar Development
- Diminishing Returns from the Government’s Drug Negotiation Program
- Would Senate Passage of an ACA Tax Credit Extension Matter?
- MGA Brief Examines State and Federal PBM Mandates
- FDA Moves to Facilitate Biosimilar Development
